How Is Discoid Lupus Erythematosus Treated?

Discoid lupus erythematosus (DLE) is a chronic, autoimmune, cutaneous form of lupus that primarily affects the skin—most commonly the face, scalp, and ears. Unlike systemic lupus erythematosus (SLE), DLE typically spares internal organs; however, approximately 5–10% of patients may eventually develop SLE over time, underscoring the importance of ongoing clinical monitoring.

First-line management centers on photoprotection and topical anti-inflammatory therapy. Daily, broad-spectrum sunscreen with SPF 50+ and physical barriers—such as wide-brimmed hats and UV-protective clothing—are essential, given that ultraviolet radiation is a major trigger for lesion flares. Topical corticosteroids—particularly high-potency formulations like clobetasol propionate—are used for active plaques, often applied under occlusion to enhance penetration. For patients who cannot tolerate or respond inadequately to steroids, topical calcineurin inhibitors (e.g., tacrolimus 0.1% ointment or pimecrolimus 1% cream) serve as effective steroid-sparing alternatives.

For widespread, recalcitrant, or scarring disease—including alopecia or disfiguring facial lesions—systemic therapy is indicated. Antimalarial agents remain the cornerstone: hydroxychloroquine (200–400 mg daily) is preferred due to its favorable safety profile and robust evidence for efficacy. In cases of partial response or intolerance, combination therapy with quinacrine or adjunctive low-dose chloroquine may be considered. Regular ophthalmologic screening is mandatory for all patients on long-term antimalarials to monitor for retinal toxicity.

In refractory cases—especially those with significant scarring, mucosal involvement, or progression despite antimalarials—second-line options include methotrexate, mycophenolate mofetil, or retinoids such as acitretin. Biologic therapies, including rituximab and belimumab, are currently investigational in DLE but may be considered off-label in select, severe, treatment-resistant scenarios under specialist supervision.

Given the risk of permanent scarring, pigmentary changes, and hair loss, early diagnosis and consistent, individualized treatment are critical. Multidisciplinary care involving dermatologists, rheumatologists, and ophthalmologists ensures comprehensive assessment and timely intervention.